



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/646,932
Filing Date	September 25, 2000
First Named Inventor	Papadopoulos, Vassilios
Group Art Unit	1642
Examiner Name	Unknown

Sheet 1 of 5

Attorney Docket No: 1941.016US2

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-20030157095A1	08/21/2003	Papadopoulos, V.	03/25/1998
	US-20060106202A1	05/18/2006	Papadopoulos, V. , et al.	01/13/2006
	US-5,350,836	09/27/1994	Kopchick, J. J., et al.	05/04/1992
	US-5,407,799	04/18/1995	Studier, F. W.	10/12/1993
	US-5,585,479	12/17/1996	Hoke, G. D., et al.	10/12/1993
	US-5,663,062	09/02/1997	Sorge, J. A., et al.	11/30/1993
	US-5,840,708	11/24/1998	Weiss, B.	12/14/1993
	US-5,948,676	09/07/1999	Chang, Y. , et al.	10/10/1996
	US-7,267,977	09/11/2007	PAPADOPOULOS, V. , et al.	03/25/1998

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
	WO-0001821A2	01/13/2000	Lal, P. , et al.	
	WO-0009549A2	02/24/2000	Papadopoulos, V.	
	WO-9949316A2	09/30/1999	Papadopoulos, V. , et al.	

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		"Application Serial No. 09-762594 (Atty Ref 1941.015US1) Final Office Action mailed 12-14-2004", 17	
		"Application Serial No. 09-762594 (Atty Ref 1941.015US1) Non Final Office Acton mailed 6-23-2004", 17 pgs	
		"Application Serial No. 09-762594 (Atty Ref 1941.015US1) Notice of Allowance mailed 8-30-2005", 4 pgs	
		"Application Serial No. 09-762594 (Atty Ref 1941.015US1) Response filed 9-23-2004 to Non Final Office Action mailed 6-23-04", 15 pgs	
		"Application Serial No. 11/331,940 (Atty Ref 1941.015US2) Preliminary Amendment filed 1-13-06", 7 pgs	
		"Application Serial No. 11/331,940 (Atty Ref 1941.015US2) Response to Restriction Requirement filed 9-12-07", 7 pgs	
		"Application Serial No. 11/331,940 (Atty Ref 1941.015US3) Restriction Requirement mailed 6-12-07", 10 pgs	
		"Australian Application No. 2004203650 Non Final Office Action mailed 10-27-06", 8 pgs	
		"Australian Application No. 2004203650 Response filed 6-7-07 to Non Final Office Action mailed 10-27-06", 11 pgs	
		"Canadian Applicattion No. 2339328 Office Action dated 2-5-07", 4 pgs	
		"Canadian Applicattion No. 2339328 Office Action mailed 5-17-06", 11pgs	

**EXAMINER****DATE CONSIDERED**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	09/646,932
<b>Filing Date</b>	September 25, 2000
<b>First Named Inventor</b>	Papadopoulos, Vassilios
<b>Group Art Unit</b>	1642
<b>Examiner Name</b>	Unknown

Sheet 2 of 5

Attorney Docket No: 1941.016US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		"Canadian Application No. 2339328 Office Action Response dated 8-1-07 to Office Action dated 5-17-06", 16 pgs	
		"Canadian Application No. 2339328 Office Action Response filed 11-2-06 to Canadian Office Action mailed 5-17-06", 7 pgs	
		"European Application No. 99 943 703.1 Office Action dated 10-21-05", 6 pgs	
		"European Application No. 99 943 703.1 Office Action dated 11-28-05", 4 pgs	
		"European Application No. 99 943 703.1 Office Action dated 4-13-05", 3 pgs	
		"European Application No. 99 943 703.1 Office Action Response dated 5-23-06", 4 pgs	
		"International Search Report in PCT/US99/18507", (June 15, 2000), 7 Pages	
		"International Search Report in PCT/US 99/05853", 5 Pages	
		AHN, A. H., et al., "The Structural and Functional Diversity of Dystrophin", <u>Nature Genetics</u> , 3, (Apr., 1993), 283-291	
		BOYLE, T P., et al., "Structure of the murine gene encoding apolipoprotein A-I.", <u>Gene</u> , 117(2), (August 15, 1992), 243-247	
		BRANCH, A. D., "A Good Antisense Molecule is Hard to Find", <u>Trends Biochem Sci.</u> , 23(2), (Feb., 1998), 45-50	
		CASALOTTI, S. O., et al., "Structure of the rat gene encoding the mitochondrial benzodiazepine receptor", <u>Gene</u> , 121(2), (Nov., 16, 1992), 377-381	
		CAWTHON, R. M., et al., "cDNA Sequence and Genomic Structure of EV12B, a Gene Lying within an Intron of the Neurofibromatosis Type 1 Gene", <u>Genomics</u> , 9, (1991), 446-460	
		DON, J, et al., "Identification and characterization of the regulated pattern of expression of a novel mouse gene, meg1, during the meiotic cell cycle", <u>Cell Growth Differ.</u> , 3(8), (August 1992), 495-505	
		DON, J., "M. musculus mRNA meg1", <u>Database EMBL [Online] AC X64455</u> , (02/21/1992), 2 Pages	
		DREXLER, H. G., et al., "Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines", <u>Leukemia and Lymphoma</u> , 9(1-2), German Collection of Microorganisms & Cell Cultures, (1993), 1-25	
		ELLIS, L. M., et al., "Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src", <u>The Journal of Biological Chemistry</u> , 273(2), (Jan. 9, 1998), 1052-1057	
		EMBLETON, M. J., et al., "Monoclonal antibodies to osteogenic sarcoma antigens", <u>Monoclonal Antibodies and Cancer</u> , Marcel Dekker, New York & Basel, (1984), 181-207	
		EVER, L, et al., "Two alternatively spliced Meig1 messenger RNA species are differentially expressed in the somatic and in the germ-cell compartments of the testis", <u>Cell Growth Differ.</u> , 10(1), (January 1999), 19-26	

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	09/646,932
<b>Filing Date</b>	September 25, 2000
<b>First Named Inventor</b>	Papadopoulos, Vassilios
<b>Group Art Unit</b>	1642
<b>Examiner Name</b>	Unknown

Sheet 3 of 5

Attorney Docket No: 1941.016US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		FARGES, R , "Site-directed mutagenesis of the peripheral benzodiazepine receptor: identification of amino acids implicated in the binding site of Ro5-4864", <u>Mol. Pharmacol.</u> , 46(6), (December 1994),1160-7	
		GALIEGUE, S. , et al., "Cloning and Characterization of PRAX-1 - A New Protein that Specifically Interacts with the Peripheral Benzodiazepine Receptor", <u>The Journal of Biological Chemistry</u> , 274(5), (Jan. 29, 1999),2938-2952	
		GARNIER, M. , et al., "Diazepam binding inhibitor is a paracrine/autocrine regulator of Leydig cell proliferation and steroidogenesis: action via peripheral-type benzodiazepine receptor and independent mechanisms", <u>Endocrinology</u> , 132(1), (January 1993),444-458	
		GLENNEY, J R., "The sequence of human caveolin reveals identity with VIP21, a component of transport vesicles.", <u>FEBS Letters</u> , 314(1), (December 7, 1992),45-48	
		HARDWICK, M. , et al., "Abstract #1569 The Peripheral-type Benzodiazepine Receptor in Human Breast Cancer", <u>Proceedings of the American Association for Cancer Research</u> , 38, (Apr.12, 1997),233	
		HARDWICK, M. , "Peripheral-Type Benzodiazepine Receptor (PBR) in Human Breast Cancer: Correlation of Breast Cancer Cell Aggressive Phenotype with PBR Expression, Nuclear Localization, and PBR-mediated Cell Proliferation and Nuclear Transport of Cholesterol", <u>Cancer Research</u> , 59(4), (1999),831-842	
		HARDWICK, M. , et al., "Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol.", <u>Cancer Research</u> , 59(4), XP002114583,(Feb. 15, 1999),831-42	
		HARRIS, P. C., et al., "Polycystic Kidney Disease 1: Identification and Analysis of the Primary Defect", <u>Journal of the American Society of Nephrology</u> , 6, (1995),1125-1133	
		HSU, "Tissue Culture", In <u>Tissue Culture Methods and Applications</u> , Kruse and Patterson, Eds, Academic Press, NY, (1973),764-767	
		KOZIKOWSKI, A. P., et al., "Synthesis and Biology of a 7-Nitro-2,1,3-benzoxadiazol-4-yl Derivative of 2-Phenylindole-3-acetamide: A Fluorescent Probe for the Peripheral-Type Benzodiazepine Receptor", <u>Journal of Medicinal Chemistry</u> , 40(16), (Aug. 1997),2435-2439	
		KRUEGER, K. E., "Peripheral-type Benzodiazepine Receptors Mediate Translocation of Cholesterol from Outer to Inner Mitochondrial Membranes in Adrenocortical Cells", <u>The Journal of Biological Chemistry</u> , 265(25), (1990),15015-15022	
		KUNKEL, P. , et al., "Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas", <u>Neuro-oncology</u> 3 (2), (2001),82-88	

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	09/646,932
<b>Filing Date</b>	September 25, 2000
<b>First Named Inventor</b>	Papadopoulos, Vassilios
<b>Group Art Unit</b>	1642
<b>Examiner Name</b>	Unknown

Sheet 5 of 5

Attorney Docket No: 1941.016US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		PAPADOPOULOS, VASSILIOS, et al., "The Peripheral-type Benzodiazepine Receptor Is Functionally Linked to Leydig Cell Steroidogenesis", <u>Journal of Biological Chemistry</u> 265(7), (March 5, 1990),3772-3779	
		PAWLIKOWSKI, M., et al., "Inhibition of Cell Proliferation of Human Gliomas by Benzodiazepines in vitro", <u>Acta Neurol Scand.</u> , 77(3), XP002114582,(Mar. 1988),231-233	
		PIKULEVA, IRINA A., "Active-site topology of bovine cholesterol side-chain cleavage cytochrome P450 (P450scc) and evidence for interaction of tyrosine 94 with the side chain of cholesterol", <u>Archives of Biochemistry and Biophysics</u> , 322(1), (September 10, 1995),189-97	
		RESNICOFF, M., et al., "Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA", <u>Cancer Immunol. Immunother.</u> , 42(1), (1996),64-68	
		RIOND, J., et al., "Molecular cloning and chromosomal localization of a human peripheral-type benzodiazepine receptor", <u>European Journal of Biochemistry</u> , 195(2), (Jan., 1991),305-311	
		RUTKA, J. T., et al., "Effects of antisense glial fibrillary acidic protein complementary DNA on the growth, invasion, and adhesion of human astrocytoma cells", <u>Cancer Res.</u> , 54(12), (June 15, 1994),3267-72	
		SAMBROOK, J., et al., <u>Molecular Cloning - a Laboratory Manual</u> , 2d Edition, Cold Spring Laboratory Press,(1989),9.47-9.62	
		SHER, I, et al., "Mutations uncouple human fibroblast growth factor (FGF)-7 biological activity and receptor binding and support broad specificity in the secondary receptor binding site of FGFs.", <u>Journal of Biological Chemistry</u> , 274(49), (December 3, 1999),35016-35022	
		SU, P., "A cDNA encoding a rat mitochondrial cytochrome P450 catalyzing both the 26-hydroxylation of vitamin D3: gonadotropic regulation of the cognate mRNA in ovaries", <u>DNA and Cell Biology</u> 9(9), (Nov., 1990),657-67	
		TIAN, J., et al., "The Expression of Native and Cultured RPE grown on Different Matrices", <u>Physiol Genomics</u> , 17, (2004),170-182	
		VAN, D. D., et al., "Monosomy 21 in hematologic diseases", <u>Cancer Genetics and Cytogenetics</u> , 241, (2003),137-141	
		WAKI, M., et al., "Antisense src expression inhibits U937 human leukemia cell proliferation in conjunction with reduction of c-myc expression.", <u>Biochem Biophys Res Commun.</u> , 201(2), (June 15, 1994),1001-7	
		YAKOVLEV, A. G., et al., "GenBank TM Database Entry", <u>Accession No. U12421</u> , (1995),	
		ZASLAV, A. L., et al., "Significance of a Prenatally Diagnosed del (10) (q23)", <u>Amer J Medical Genetics</u> , 107, (2002),174-176	

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

<b>Application Number</b>	09/646,932
<b>Filing Date</b>	September 25, 2000
<b>First Named Inventor</b>	Papadopoulos, Vassilios
<b>Group Art Unit</b>	1642
<b>Examiner Name</b>	Unknown

Sheet 4 of 5

Attorney Docket No: 1941.016US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		LI, HUA , et al., "Identification, Localization, and Funtion in Steroidogenesis of PAP7: A Peripheral-Type Benzodiazepine Receptor- and PKA (RI?N)-Associated Protein", <u>Molecular Endocrinology</u> 15(12), (2001),2211-2228	
		LI, H. , et al., "M. musculus peripheral benzodiazepine receptor associated protein", <u>Database EMBL [Online]</u> AC AF022770, (October 1, 1997),1 page	
		LI, H. , et al., "Peripheral-type benzodiazepine receptor function in cholesterol transport. Identification of a putative cholesterol recognition/interaction amino acid sequence and consensus pattern", <u>Endocrinology</u> , 139(12), (1999),4991-4997	
		LIU, JUN , et al., "Molecular cloning, chromosomal localization of human peripheral-type benzodiazepine receptor- and protein kinase A regulatory subunit type 1A (PRKAR1A)-associated protein PAP7 and studies in PRKAR1A mutant cells and tissues", <u>The FASEB Journal</u> , express article, 10.1096/fj.02-1066fje,(April 8, 2003),27 pgs.	
		LU, C. , et al., "Endogenous Interleukin 6 Can Function as an in Vivo Growth-stimulatory Factor for Advanced-Stage Human Melanoma Cells", <u>Clinical Cancer Research</u> , 2(8), (1996),1417-1425	
		MARRA, M. , et al., "mo98e12.rl Stratagene mouse testis (#937308) Mus musculus cDNA clone", <u>Database EMBL [Online]</u> AC AA174581, (Dec. 31, 1996),2 Pages	
		MIETTINEN, H. , "Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas: relationship to cell proliferation", <u>Cancer Research</u> , 55(12), (June 15, 1995),2691-2695	
		MOSER, P. C., "Potentiation of 5-Methoxy-N,N-Dimethyltryptamine-Induced Head-Twitches by Diazepam: Evidence for Involvement of Adenosine Uptake Inhibition", <u>Drug Development Research</u> , 30(4), (1993),213-218	
		PAPADOPOULOS, V. , et al., "CHOLESTEROL RECOGNITION SEQUENCE", <u>US Patent Application Ser. No. 09/623,922</u> , filed September 11, 2000 (1941.017US1).	
		PAPADOPOULOS, V. , et al., "PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR: A TOOL FOR DETECTION, DIAGNOSIS, PROGNOSIS, AND TREATMENT OF CANCER", <u>US Patent Application Ser. No. 09/646,932</u> , filed September 25, 2000 (1941.016US2).	
		PAPADOPOULOS, V. , "Structure and function of the peripheral-type benzodiazepine receptor in steroidogenic cells", <u>Proceedings of the Society for Experimental Biology &amp; Medicine</u> , 217(2), (February 2, 1998),130-142	
		PAPADOPOULOS, V. , "Targeted Disruption of the Peripheral-Type Benzodiazepine Receptor Gene Inhibits Steroidogenesis in the R2C Leydig Tumor Cell Line", <u>The Journal of Biological Chemistry</u> , 272(51), (1997),32129-32135	

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached